Novo Nordisk A/S' CEO transition sparks governance concerns, but internal succession ensures stability. Click for my updated ...

COPENHAGEN (Reuters) - Wegovy-maker Novo Nordisk (NYSE: NVO) ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the ...

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the competitive weight-loss drug market.

The company behind the weight loss sensation that transformed bodies and bank accounts across America just showed its own CEO ...

Eli Lilly saw a 26% spike in call option activity, hinting that investors are feeling unusually optimistic—or just love drama ...

Jorgensen became CEO in January 2017 and the company’s market capitalization has more than tripled during his tenure. Novo was first to market with Wegovy and its sister drug Ozempic for diabetes, but ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

However, many on Wall Street believe that better days lie ahead for Novo Nordisk. Analysts expect this obesity drug stock to ...

Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential ...

Eli Lilly and Company (NYSE:LLY) is a leading medicine company which discovers, develops, manufactures, and markets products ...

Healthcare Opportunities Fund seems to offer a solid balance of capital stability and income. Read why THQ CEF is a Hold.

Many economists expect muted U.S. economic growth in the coming quarters, and the first quarter's negative GDP growth makes a mild recession a real possibility. It may become difficult for ...